Progress, Potential, and Possibilities Podcast / Show Craig Thompson - CEO, Cerevance - Advancing Novel, Precision Neuroscience Therapeutics
Craig Thompson is the Chief Executive Officer of Cerevance ( https://www.cerevance.com/about ), a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology, a machine learning platform that helps measure precise levels at which thousands of genes are expressed in any cell type in any region of the brain, and then map those genes to specific diseased and healthy brain states. Most recently, Mr. Thompson was President and Chief Executive Officer of Neurana Pharmaceuticals. Prior to Neurana, Mr. Thompson was President and Chief Executive Officer of Anthera Pharmaceuticals. Mr. Thompson's previous biotech experience includes Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics where he was involved in the $707M up front acquisition of Trius by Cubist Pharmaceuticals, as well as a partnership with Bayer Pharma AG. Prior to Trius, Mr. Thompson served in various global and U.S. roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and ultimately served as Vice President of Marketing for Pfizer’s Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc including leading the partnership with Schering Plough. Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.